These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32268935)

  • 21. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
    Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.
    Kang B; Lee Y; Lee K; Choi YO; Choe YH
    Inflamm Bowel Dis; 2018 Feb; 24(3):607-616. PubMed ID: 29390113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
    Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Lee Y; Rho YH
    Ann Rheum Dis; 2018 Feb; 77(2):234-240. PubMed ID: 29042358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Katsanos KH; Papamichael K; Cheifetz AS; Christodoulou DK
    Inflamm Bowel Dis; 2018 Feb; 24(3):465-466. PubMed ID: 29462402
    [No Abstract]   [Full Text] [Related]  

  • 25. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
    Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Queiroz NSF; Saad-Hossne R; FrÓes RSB; Penna FGCE; Gabriel SB; Martins AL; Teixeira FV
    Arq Gastroenterol; 2020; 57(3):232-243. PubMed ID: 32935741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
    Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
    Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
    Danese S; Fiorino G
    Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
    Benucci M; Gobbi FL; Bandinelli F; Damiani A; Infantino M; Grossi V; Manfredi M; Parisi S; Fusaro E; Batticciotto A; Sarzi-Puttini P; Atzeni F; Meacci F
    Immunol Res; 2017 Feb; 65(1):419-422. PubMed ID: 27449503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
    Ebada MA; Elmatboly AM; Ali AS; Ibrahim AM; Fayed N; Faisal AF; Alkanj S
    Int J Colorectal Dis; 2019 Oct; 34(10):1633-1652. PubMed ID: 31492986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, Canada.
    Hoang TT; Reid J; Galorport C; Bressler B; Leung Y; Rosenfeld G
    J Can Assoc Gastroenterol; 2024 Aug; 7(4):299-305. PubMed ID: 39139221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
    Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
    Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.
    Dapavo P; Vujic I; Fierro MT; Quaglino P; Sanlorenzo M
    J Am Acad Dermatol; 2016 Oct; 75(4):736-739. PubMed ID: 27473452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.